Variables | Number of | Number of | Survivability (%) | p-valuea | |||||
---|---|---|---|---|---|---|---|---|---|
Patients, n | Events, | 2 days | 4 days | 6 days | 8 days | 10 days | |||
n | |||||||||
Overall Survivability | 185 | 25 | 94.7 | 88.0 | 76.4 | 63.1 | 50.5 | Â | |
Age category | Â | Â | Â | Â | Â | Â | Â | 0.905 | |
 | ≤ 61 years | 95 | 13 | 94.4 | 87.7 | 75.6 | 61.9 | 51.6 |  |
 | ≥ 62 years | 90 | 12 | 96.7 | 95.0 | 88.3 | 69.6 | 52.2 |  |
Gender | Â | Â | Â | Â | Â | Â | Â | Â | 0.895 |
 | Male | 92 | 15 | 94.0 | 86.1 | 69.1 | 62.2 | 46.6 |  |
 | Female | 68 | 13 | 96.4 | 91.8 | 78.7 | 65.6 | 32.8 |  |
Ethnicity | Â | Â | Â | Â | Â | Â | Â | Â | 0.750 |
 | Malay | 87 | 9 | 91.8 | 87.0 | 87.0 | 65.2 | 65.2 |  |
 | Chinese | 64 | 10 | 89.9 | 85.1 | 61.3 | 49.0 | 0.0 |  |
 | Indian | 25 | 3 | 75.0 | 75.0 | 75.0 | 50.0 | 0.0 |  |
 | Others | 9 | 3 | 87.5 | 87.5 | 87.5 | 87.5 | 43.0 |  |
Smoking status | Â | Â | Â | Â | Â | Â | Â | 0.124 | |
 | No | 137 | 23 | 93.0 | 86.9 | 76.8 | 61.7 | 48.0 |  |
 | Yes | 48 | 2 | 91.7 | 91.7 | 68.8 | 68.8 | 68.8 |  |
Stroke category |  |  |  |  |  |  |  | < 0.001* | |
 | Ischemic stroke | 171 | 14 | 96.9 | 94.6 | 86.6 | 69.6 | 60.9 |  |
 | Hemorrhagic stroke | 14 | 11 | 70.7 | 47.1 | 28.3 | 28.3 | 14.1 |  |
Stroke episode |  |  |  |  |  |  |  | < 0.001* | |
 | First | 137 | 9 | 96.0 | 93.7 | 85.9 | 76.3 | 61.1 |  |
 | Recurrent | 48 | 16 | 91.1 | 79.5 | 63.6 | 49.5 | 39.6 |  |
Number of comorbidities | Â | Â | Â | Â | Â | Â | Â | 0.136 | |
 | ≤ 2comorbidities | 107 | 10 | 96.5 | 93.7 | 93.7 | 75.0 | 53.5 |  |
 | ≥ 3comorbidities | 78 | 15 | 92.5 | 82.7 | 61.9 | 53.1 | 26.5 |  |
Number of medications | Â | Â | Â | Â | Â | Â | Â | 0.118 | |
 | ≤ 10medications | 103 | 10 | 94.2 | 83.7 | 73.2 | 73.2 | 0.0 |  |
 | ≥ 11medications | 82 | 15 | 95.6 | 90.6 | 79.0 | 68.5 | 60.8 |  |
Anti-platelets | Â | Â | Â | Â | Â | Â | Â | 0.014* | |
 | No | 29 | 17 | 82.6 | 67.6 | 53.8 | 48.4 | 41.5 |  |
 | Yes | 156 | 8 | 99.4 | 91.4 | 83.1 | 69.3 | 46.2 |  |
Statins |  |  |  |  |  |  |  |  | < 0.001* |
 | No | 33 | 18 | 84.0 | 67.4 | 49.1 | 35.1 | 28.1 |  |
 | Yes | 152 | 7 | 97.1 | 92.5 | 85.9 | 85.9 | 68.7 |  |
Proton pump inhibitors | Â | Â | Â | Â | Â | Â | Â | 0.863 | |
 | No | 49 | 5 | 93.9 | 82.1 | 82.1 | 41.1 | 41.1 |  |
 | Yes | 136 | 20 | 94.9 | 85.8 | 74.8 | 65.1 | 40.5 |  |
Anti-diabetic | Â | Â | Â | Â | Â | Â | Â | 0.266 | |
 | No | 112 | 18 | 93.6 | 85.6 | 70.3 | 57.5 | 41.1 |  |
 | Yes | 73 | 7 | 96.4 | 91.8 | 71.4 | 71.4 | 35.7 |  |
Anti-hypertensive | Â | Â | Â | Â | Â | Â | Â | 0.046* | |
 | No | 127 | 20 | 94.2 | 83.6 | 71.3 | 55.1 | 45.9 |  |
 | Yes | 58 | 5 | 95.9 | 87.2 | 87.2 | 87.2 | 65.4 |  |
Anti-infective | Â | Â | Â | Â | Â | Â | Â | 0.005* | |
 | No | 150 | 5 | 97.5 | 89.3 | 89.3 | 59.6 | 59.6 |  |
 | Yes | 35 | 20 | 85.7 | 73.0 | 61.9 | 53.1 | 42.5 |  |